Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen (Ygalo®), an alkylating peptide, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment of hematological cancers, and in particular multiple myeloma.
ASH 2018 – presentations and articles
During the American Hematology Meeting (ASH), Oncopeptides presented data from two ongoing studies, ANCHOR and HORIZON. The ANCHOR Poster, the oral presentation of HORIZON and two external links regarding publications in the media.
Melflufen (Ygalo®), a peptide conjugated alkylator belonging to a novel class of peptidase-enhanced compounds, targets the multiple myeloma (MM) cells with a unique mechanism of action. Aminopeptidases are enzymes found in all cells but are over-expressed in several cancers including MM. Melflufen selectively targets MM cells through aminopeptidase-driven accumulation. In vitro experiments show a 50-fold enrichment of the active substance in MM cells compared with administration of equal amount of an alkylator not enriched by aminopeptidases.
Oncopeptides CEO Jakob Lindberg held a presentation at Jefferies 2018 Healthcare conference in London November 14. The presentation was also recorded as a webcast.
Melflufen (Ygalo®), a peptide conjugated alkylator belonging to a novel class of peptidase-enhanced compounds, targets the multiple myeloma (MM) cells with a unique mechanism of action.